ABSTRACr To investigate the role of endorphins in central respiratory control, the effect of naloxone, a specific opiate antagonist, on resting ventilation and ventilatory control was investigated in a randomised double-blind, placebo-controlled study of normal subjects and patients with chronic airways obstruction and mild hypercapnia due to longstanding chronic bronchitis. In 13 normal subjects the ventilatory response to hypercapnia increased after an intravenous injection of naloxone (0-1 mg/kg), ventilation (VE) at a Pco2 of 8-5 kPa increasing from 55 6 + SEM 6-2 to 75-9 + 8-2 1 min-' (p < 0 001) and the AVE/APCo2 slope increasing from 28-6 + 4 4 to 34-2 + 4-2 1 min-' kPa-' (p < 0 05). There was no significant change after placebo (saline) injection. Naloxone had no effect on resting ventilation or on the ventilatory response to hypoxia in normal subjects. In 
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Exogenous opiates have long been known to depress respiration and diminish the ventilatory response to hypoxia and hypercapnia. ' In normal man naloxone had no effect on tidal volume or on end-tidal carbon dioxide. " In a small study naloxone had no significant effect on ventilatory responses to hypercapnia or hypoxia in normal subjects. '2 In patients with chronic airway obstruction, however, naloxone increased the ability to compensate for an additional inspiratory resistance and in some patients increased the response to carbon dioxide. '3 This study, however, lacked placebo controls, making interpretation difficult. As the role of endogenous opiates in the control of breathing remains uncertain, we have studied the effects of naloxone on respiration and ventilatory control in normal subjects and in patients with chronic airway obstruction in a double-blind randomised study. To avoid the effect of a mouthpiece, resting ventilation was measured non-invasively from body surface movements with a respiratory inductance plethysmograph (Respitrace) consisting of thoracic and abdominal belts. This was calibrated by an isovolume manoeuvre as previously described"' and gave an accuracy compared with simultaneous spirometric measurements in the semi-recumbent posture of 10% in both normal subjects and patients with airways obstruction. Measurements were made with the subject lying quietly and when ventilation showed little variation a sample over five minutes was recorded (Sanborn recorder) with a paper speed of 1 cm/s. Resting respiratory frequency, tidal volume (VT), inspiratory timing (Ti/Ttot), and mean inspiratory flow (VT/Ti) were measured. '5 Respiratory sensitivity to carbon dioxide was measured by a modification of the rebreathing method of Read. 16 Subjects rebreathed a 5% carbon dioxide in 95% oxygen gas mixture from an anaesthetic bag contained in a glass bottle and ventilation was measured by a dry gas meter (Parkinson Cowan CD4). Gas was continuously sampled at the mouth by an infared carbon dioxide meter (Capnograph, Godart) and the sampled gas was returned to the rebreathing bag. In the patients mouth pressure in the first 0 1 second of an occluded breath (P0.,) was measured with a specially designed valve, and measurements were made every 30 seconds during rebreathing. Po.1 is independent of the compliance and flow resistance of the lung,'"18 and therefore provides a better index of central respiratory drive than does ventilation in patients with airway obstruction, whose ventilatory response may be limited. Results were analysed by plotting ventilation (VE) and Po.1 against Pco2. The resulting plots were linear and the slopes determined by linear regression analysis (AVE/APCo2; AP0. I/APCo2). VE or P0.1 at a fixed Pco2 (8-5 kPa) was also determined.
Hypoxic responses were measured in normal subjects by a modification of the method of Rebuck and Campbell. '9 Subjects rebreathed a gas mixture of 7% carbon dioxide in air and ventilation was measured as above. Before rebreathing subjects breathed quietly on the mouthpiece connected to air and end-tidal Pco2 was estimated. This was then maintained at the same level (+0 2%) throughout the rebreathing period by a scrub circuit (containing soda lime) with a variable flow. Arterial oxygen saturation (Sao2) was measured continuously by an ear oximeter (Hewlett Packard). Rebreathing continued until the Sao2 fell to 70%. The resulting plots of VE against Sao2 were linear and the slopes (AVE/ASaO2) were determined by linear regression analysis.
Baseline measurements of resting ventilation and hypercapnia response were made in all subjects, and hypoxic response in eight normal subjects. Subjects were then given either naloxone 0-1 mg/kg or volume-matched saline in double-blind manner on consecutive days. This large dose of naloxone was chosen to block endogenous opiate receptors completely. Measurements were repeated 10 minutes after injection, which is sufficient time to allow penetration of naloxone into the brain; and studies were completed within 40 minutes of injection, which is well within the half life of the drug.20 No subjects knew whether they had received naloxone or placebo and no adverse effects were reported. Heart and whereas naloxone is a potent antagonist against mu receptors it is much less potent against delta and kappa receptors, which could also play a part in the central control of respiration. Because the effects of naloxone are small the clinical application of these findings is probably limited. Although naloxone lacks appreciable side effects, even in large doses, it is obviously less potent than other analeptics, although occasional patients may show large responses. Our studies do show that endorphins have a modulatory role in the respiratory response to carbon dioxide in both normal subjects and patients with chronic airflow obstruction, and also have an inhibitory effect on tidal breathing in these patients. Changes in medullary endorphin concentrations may therefore influence the control of 
